BVS
Bioventus Inc
NASDAQ: BVS · HEALTHCARE · MEDICAL DEVICES
$9.87
+2.07% today
Updated 2026-04-30
Market cap
$682.47M
P/E ratio
30.58
P/S ratio
1.20x
EPS (TTM)
$0.33
Dividend yield
—
52W range
$6 – $11
Volume
0.4M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
4.0
Growth
C5.0
Quality
C+5.5
Profitability
C+6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$14.80
+49.95%
12-Month target
$9.16
-7.19%
Intrinsic (DCF)
$36.03
Margin of safety
+77.57%
2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $36.69M — positive
+ 77.57% below intrinsic value
Risks
- Thin margins at 4.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $512.12M | $512.35M | $573.28M | $568.09M | $568.09M |
| Net income | $-158.70M | $-156.23M | $-33.54M | $22.73M | $14.76M |
| EPS | — | — | — | — | $0.33 |
| Free cash flow | $-15.02M | $7.98M | $37.79M | $71.41M | $36.69M |
| Profit margin | -30.99% | -30.49% | -5.85% | 4.00% | 4.00% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-20 | SINGLETON, MARK LEONARD | Sale | 18,625 | — |
| 2026-03-20 | SINGLETON, MARK LEONARD | Buy | 18,625 | — |
| 2026-03-20 | SINGLETON, MARK LEONARD | Sale | 8,091 | $8.64 |
Peer comparison
Smart narrative
Bioventus Inc trades at $9.87. representing a P/E of 30.58x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. TTM revenue stands at $568.09M. with profit margins at 4.00%. Our DCF model estimates intrinsic value at $36.03.
Frequently asked questions
What is Bioventus Inc's stock price?
Bioventus Inc (BVS) trades at $9.87.
Is Bioventus Inc overvalued?
Smart Value Score 49/100 (Grade C, Sell). DCF value $36.03.
What is the price target of Bioventus Inc (BVS)?
The analyst target price is $14.80, representing +49.9% upside from the current price of $9.87.
What is the intrinsic value of Bioventus Inc (BVS)?
Based on our DCF model, intrinsic value is $36.03, a +77.6% margin of safety versus $9.87.
What is the future stock price of BVS by 2030?
Our revenue-driven model estimates Bioventus Inc could reach $13.31 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.
What is Bioventus Inc's revenue?
TTM revenue is $568.09M.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.20x
ROE13.20%
Beta0.69
50D MA$9.06
200D MA$7.69
Shares out0.07B
Float0.03B
Short ratio—
Avg volume0.4M
Performance
1 week+1.65%
1 month+8.11%
3 months+26.21%
YTD+32.66%
1 year—
3 years—
5 years—